ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy ...

Of 34 CMML treatment-naïve participants enrolled and treated with lenzilumab plus azacitidine, 22 have evaluable responses in the first twelve months of follow-up - Building upon previously reported ...

MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...

Bleeding gums need not always be associated with leukaemia however frequent bleeding in gums may be a sign of something more ...

A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, representing a potential paradigm shift if approved by the FDA, while highlighting ...

Scientists find link between where you live and childhood leukemia - New research has found that millions of children are at ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...

Panelists highlight that patient advocacy is crucial in improving high-risk acute myeloid leukemia (AML) outcomes by ...

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of ...

A large new study has confirmed the clinical relevance of a pharmacogenomic score that could help tailor leukaemia treatment ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia Clinical data showing ...